Chinese Medical Software Firm Taimei Raises USD 176 Million from Tencent, Hillhouse, Others

Further participating in the round were Morningside Venture Capital, Matrix Partners China, Zheshang Venture Capital, SB China Capital, Cowin Capital, Ivy Capital, Weilai Qichuang Fund, and Fanzhuo Capital.

Taimei runs TrialOS, a platform that involves the different stakeholders in the pharmaceutical sector, including hospitals, drug makers, regulators, and patients. TrialOS consists of more than 20 applications, managing clinical research projects, clinical trial documents, patient data, and a system that alerts on adverse drug reactions during trials, among others.

The company claims that TrialOS supports one third of registered clinical research in China and one fifth of adverse drug reaction submissions. Taimei also provides software that helps drug firms in their marketing efforts and to gain licenses from regulators.